143 related articles for article (PubMed ID: 35522890)
21. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
22. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
[TBL] [Abstract][Full Text] [Related]
23. Distinct clinicopathological and genomic features in solid and basaloid adenoid cystic carcinoma of the breast.
Ji J; Zhang F; Duan F; Yang H; Hou J; Liu Y; Dai J; Liao Q; Chen X; Liu Q
Sci Rep; 2022 May; 12(1):8504. PubMed ID: 35590093
[TBL] [Abstract][Full Text] [Related]
24. Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels.
Evans MF; Vacek PM; Sprague BL; Stein GS; Stein JL; Weaver DL
J Cell Biochem; 2020 Feb; 121(2):1736-1746. PubMed ID: 31595577
[TBL] [Abstract][Full Text] [Related]
25. Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas).
Marchiò C; Weigelt B; Reis-Filho JS
J Clin Pathol; 2010 Mar; 63(3):220-8. PubMed ID: 20203221
[TBL] [Abstract][Full Text] [Related]
26. Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.
Reyes C; Jorda M; Gomez-Fernández C
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):283-6. PubMed ID: 22935826
[TBL] [Abstract][Full Text] [Related]
27. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ.
Liu Y; Yu T
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11181-11191. PubMed ID: 37354223
[TBL] [Abstract][Full Text] [Related]
29. A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma.
Bishop JA; Yonescu R; Epstein JI; Westra WH
Hum Pathol; 2015 Aug; 46(8):1204-8. PubMed ID: 26089205
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic value of MYB protein expression in adenoid cystic carcinoma and status of MYB gene copy number].
Huo Z; Zeng X; Wu S; Wu H; Meng Y; Liu Y; Luo Y; Cao J; Liang Z
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):582-6. PubMed ID: 26705183
[TBL] [Abstract][Full Text] [Related]
31. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms.
Brill LB; Kanner WA; Fehr A; Andrén Y; Moskaluk CA; Löning T; Stenman G; Frierson HF
Mod Pathol; 2011 Sep; 24(9):1169-76. PubMed ID: 21572406
[TBL] [Abstract][Full Text] [Related]
32. A novel EWSR1-MYB fusion in an aggressive advanced breast adenoid cystic carcinoma with mixed classical and solid-basaloid components.
Lei T; Shi Y; Da W; Xia C; Wang H
Virchows Arch; 2023 Nov; 483(5):717-722. PubMed ID: 36719454
[TBL] [Abstract][Full Text] [Related]
33. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
[TBL] [Abstract][Full Text] [Related]
34. The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features.
Schwartz CJ; Brogi E; Marra A; Da Cruz Paula AF; Nanjangud GJ; da Silva EM; Patil S; Shah S; Ventura K; Razavi P; Norton L; D'alfonso T; Weigelt B; Pareja F; Reis-Filho JS; Wen HY
Mod Pathol; 2022 Feb; 35(2):193-201. PubMed ID: 34599282
[TBL] [Abstract][Full Text] [Related]
35. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
Mills MN; Yang GQ; Oliver DE; Liveringhouse CL; Ahmed KA; Orman AG; Laronga C; Hoover SJ; Khakpour N; Costa RLB; Diaz R
Eur J Cancer; 2018 Jul; 98():48-58. PubMed ID: 29870876
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands.
Šteiner P; Andreasen S; Grossmann P; Hauer L; Vaněček T; Miesbauerová M; Santana T; Kiss K; Slouka D; Skálová A
Virchows Arch; 2018 Oct; 473(4):471-480. PubMed ID: 29619555
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
[TBL] [Abstract][Full Text] [Related]
38. MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts.
Togashi Y; Dobashi A; Sakata S; Sato Y; Baba S; Seto A; Mitani H; Kawabata K; Takeuchi K
Mod Pathol; 2018 Jun; 31(6):934-946. PubMed ID: 29410490
[TBL] [Abstract][Full Text] [Related]
39. Detection of MYB Alterations and Other Immunohistochemical Markers in Primary Cutaneous Adenoid Cystic Carcinoma.
North JP; McCalmont TH; Fehr A; van Zante A; Stenman G; LeBoit PE
Am J Surg Pathol; 2015 Oct; 39(10):1347-56. PubMed ID: 26076064
[TBL] [Abstract][Full Text] [Related]
40. Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study.
Jalaly JB; Sanati S; Chernock RD; Dibe DG; El-Mofty SK
Head Neck Pathol; 2018 Dec; 12(4):488-492. PubMed ID: 29302899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
